BFM
DMRA

Boothbay Fund Management’s Damora Therapeutics DMRA Stock Holding History

Boothbay Fund Management’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-110,441
Closed -$2.86M – 2392
2026
Q1 		$2.86M Buy
110,441
+14,643
+15% +$376K 0.04% 493
2025
Q4 		$2.2M Buy
+95,798
New +$1.66M 0.03% 534

Other funds holding DMRA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCP
Remedium Capital Partners Fort Lauderdale, Florida $452M AUM

Boothbay Fund Management's DMRA Position: Q2 2026 in Review

Boothbay Fund Management sold out of Damora Therapeutics (DMRA) in Q2 2026, closing a stake of 110,441 shares — an estimated $2.86M sold.

Boothbay Fund Management first reported a position in DMRA in Q4 2025 and held it in 2 quarters. The position peaked at $2.86M in Q1 2026. 104 funds tracked by Wall St. Rank hold DMRA as of Q2 2026.

  • Boothbay Fund Management reported no remaining Damora Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Boothbay Fund Management sold 110,441 Damora Therapeutics shares in Q2 2026, an estimated $2.86M.
  • Boothbay Fund Management first reported a position in Damora Therapeutics in Q4 2025 and held it in 2 quarters.
  • Boothbay Fund Management's Damora Therapeutics position peaked at $2.86M in Q1 2026.
  • 104 funds tracked by Wall St. Rank held Damora Therapeutics as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.